Valion Bio, Inc. Warrant Down Round Feature Increase Decrease In Equity Amount1
Valion Bio, Inc. (VBIO) reported Warrant Down Round Feature Increase Decrease In Equity Amount1 of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1 · last filed 2026-08-14
- Valion Bio, Inc. warrant down round feature increase decrease in equity amount1 for the quarter ending 2026-06-30 was $0.00.
- Valion Bio, Inc. warrant down round feature increase decrease in equity amount1 for the quarter ending 2025-09-30 was $0.00.
- Valion Bio, Inc. warrant down round feature increase decrease in equity amount1 for fiscal 2025 was $0.00.
| Period end | Warrant Down Round Feature Increase Decrease In Equity Amount1 3 month | Warrant Down Round Feature Increase Decrease In Equity Amount1 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-14 | |
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |